Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease

D.V. Mayblyum, J.A. Becker, H.I.L. Jacobs, R.F. Buckley, A.P. Schultz, J. Sepulcre, J.S. Sanchez, Z.B. Rubinstein, S.R. Katz, K.A. Moody, P. Vannini, K.V. Papp, D.M. Rentz, J.C. Price, R.A. Sperling, K.A. Johnson, B.J. Hanseeuw*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Objective To compare how structural MRI, fluorodeoxyglucose (FDG), and flortaucipir (FTP) PET signals predict cognitive decline in high-amyloid vs low-amyloid participants with the goal of determining which biomarker combination would result in the highest increase of statistical power for prevention trials. Methods In this prospective cohort study, we analyzed data from clinically normal adults from the Harvard Aging Brain Study with MRI, FDG, FTP, and Pittsburgh compound B (PiB)-PET acquired within a year and prospective cognitive evaluations over a mean 3-year follow-up. We focused analyses on predefined regions of interest: inferior temporal, isthmus cingulate, hippocampus, and entorhinal cortex. Cognition was assessed with the Preclinical Alzheimer's Cognitive Composite. We evaluated the association between biomarkers and cognitive decline using linear mixed-effect models with random intercepts and slopes, adjusting for demographics. We generated power curves simulating prevention trials. Results Data from 131 participants (52 women, age 73.98 +/- 8.29 years) were analyzed in the study. In separate models, most biomarkers had a closer association with cognitive decline in the high-PiB compared to the low-PiB participants. A backward stepwise regression including all biomarkers demonstrated that only neocortical PiB, entorhinal FTP, and entorhinal FDG were independent predictors of subsequent cognitive decline. Power analyses revealed that using both high PiB and low entorhinal FDG as inclusion criteria reduced 3-fold the number of participants needed in a hypothetical trial compared to using only high PiB. Discussion In preclinical Alzheimer disease, entorhinal hypometabolism is a strong and independent predictor of subsequent cognitive decline, making FDG a potentially useful biomarker to increase power in clinical trials. Classification of Evidence This study provides Class II evidence that in people with preclinical Alzheimer disease, entorhinal hypometabolism identified by FDG-PET is predictive of subsequent cognitive decline.
Original languageEnglish
Pages (from-to)E2933-E2943
Number of pages11
Issue number24
Publication statusPublished - 15 Jun 2021


  • BETA


Dive into the research topics of 'Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease'. Together they form a unique fingerprint.

Cite this